© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Renal Cell Carcinoma
Bettering Survival With Telaglenastat Combinations in RCC
May 26, 2020
In an interview with Targeted Oncology, Chung-Han Lee, MD, PhD, provided background on the phase 2 ENTRATA study and discussed the next steps with telaglenastat in the RCC treatment landscape.
Tivozanib Could Be Evaluated in Combination Regimens for Renal Cell Carcinoma
May 20, 2020
Vivek Subbiah, MD, discusses the potential to combine tivozanib with other agents, particularly ipilimumab, as treatment of patients with renal cell carcinoma.
Promising Efficacy and Safety With Seleno-L-Methionine Plus Axitinib in ccRCC
May 16, 2020
Yousef Zakharia, MD, discussed recent phase I data from a study of seleno-L-methionine in combination with axitinib as treatment of patients with previously treated or relapsed clear cell renal cell carcinoma. Zakharia recently presented these data as part of the American Urological Association Virtual Experience platform for the 2020 AUA Annual Meeting.
The Impact of SETD2 on Tumor Microenvironment in Clear Cell RCC
May 12, 2020
In an interview with Targeted Oncology, Scott Haake, MD, discussed the current understandings of SETD2 mutations in clear cell renal cell carcinoma and the findings presented at the 2019 International Kidney Cancer Symposium.
Novel MK-6482 Molecule Targeting HIF-2 Yields Responses in Clear Cell Renal Cell Carcinoma
May 11, 2020
In an interview with Targeted Oncology, Toni K. Choueiri, MD, discussed the findings from the phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell RCC, which were presented at the 2020 Genitourinary Cancers Symposium.
FDA Grants RMAT Designation to Ilixadencel in Metastatic RCC
May 08, 2020
"We are very excited to have received the RMAT designation for ilixadencel in kidney cancer as it recognizes both the potential of our novel therapeutic approach as well as the clear need for viable therapies to address this difficult-to-treat disease."
Lenvatinib Plus Pembrolizumab Deemed Valid Treatment for Renal Cell Carcinoma
May 01, 2020
“The results that we’ve seen do suggest that there is some interaction between the two drugs, despite ongoing debate of whether this regimen after progression on a PD-1 inhibitor could be beneficial in clear cell renal cell carcinoma."
Using Combination Therapy as Treatment of Non-Clear Cell RCC
April 25, 2020
Bradley McGregor, MD, discusses a small study that evaluated the combination of atezolizumab and bevacizumab for the treatment of patients with non-clear cell renal cell carcinoma.
Cabozantinib Improves Survival in Phase III METEOR Trial of Advanced Renal Cell Carcinoma
April 16, 2020
Cabozantinib achieved improvements in the progression-free survival, overall survival, and objective response rate in patients with previously treated advanced renal cell carcinoma compared with everolimus, according to data from the phase III METEOR study.
FDA Grants Pembrolizumab Priority Review for TMB-High Tumors
April 07, 2020
The FDA has accepted and granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high who have progressed following prior treatment and who have no satisfactory alternative treatment options.